CASIA OpenIR  > 中国科学院分子影像重点实验室
Biomimetic camouflaged nanoparticle-based folfirinox platform for optimizing clinical pancreatic cancer treatment
Wang, Qian1,2; Wang, Zihua3; Li, Zhangfu4,5; Li, Dan6; He, Fangfei7; Wang, Kun2; Tian, Jie2; Zhao, Xinming1
Source PublicationNANO TODAY
ISSN1748-0132
2023-02-01
Volume48Pages:11
Corresponding AuthorWang, Zihua(wangzh@fjmu.edu.cn) ; Wang, Kun(kun.wang@ia.ac.cn) ; Tian, Jie(jie.tian@ia.ac.cn) ; Zhao, Xinming(xinmingzh2017@yeah.net)
AbstractThe most effective treatment of pancreatic cancer (PC) is known as mFOLFIRINOX scheme. However, this regimen has relatively severe toxic effects and are commonly restricted to patients with sound physique, which is poor in drug-selectivity, non-specific causing serious toxicity, greatly limits clinical application. Safer and more effective strategy seamlessly and synchronously is needed as advanced treatments for pancreatic cancer in future. In this report, we exploit a biomimetic nanoparticle-based platform for optimizing mFOL-FIRINOX regimen. By coating pancreatic cancer cell membrane (PCCM) onto the surface of polymeric cores that loaded with mFOLFIRINOX, we prepare PCCM-cloaked nanoparticles, namely CNP@folfirinox, which inherit the antigenic exterior structure and associated functions of PC cells. The resulting CNP@folfirinox displays a core-shell nanostructure, which consisting of polymeric core and cancer cell membrane shell with suitable size and surface charge. Particularly, owing to inheriting the inherent membrane protein expressions profile, CNP@folfirinox exhibits prominent advantages in homologous homing to tumor tissue and deep penetration. It also shows lower side effects compared to extensive mFOLFIRINOX i.v. administration with no appreciable toxicity in other organs outside the tumor in vivo. Meanwhile, CNP@folfirinox is endowed with the "Don't eat me" privilege, hard for the immune system to recognize and less reticuloendothelial system uptake, with prolonged blood circulation, therefore improving delivery efficiency of drug after intravenous administration. Thus, this work reshapes a promising paradigm for more safe and more effective mFOLFIR-INOX strategy for further clinical pancreatic cancer treatment. (c) 2022 Elsevier Ltd. All rights reserved.
KeywordPancreatic cancer MFOLFIRINOX regimen Cell membrane biomimetic platform Drug delivery Multimodal visualization
DOI10.1016/j.nantod.2022.101733
WOS KeywordDRUG-DELIVERY ; TOLERABILITY ; COMBINATION ; EFFICACY
Indexed BySCI
Language英语
Funding ProjectMinistry of Science and Technology of China[2017YFA0205200] ; National Natural Science Foundation of China[81901813] ; National Natural Science Foundation of China[62027901] ; National Natural Science Foundation of China[81227901] ; National Natural Science Foundation of China[92159305] ; CAMS Innovation Fund for Medical Science[2021-I2M-CT-B-067] ; Joint Funds for the Innovation of Science and Technology Fujian Province[2019Y9001]
Funding OrganizationMinistry of Science and Technology of China ; National Natural Science Foundation of China ; CAMS Innovation Fund for Medical Science ; Joint Funds for the Innovation of Science and Technology Fujian Province
WOS Research AreaChemistry ; Science & Technology - Other Topics ; Materials Science
WOS SubjectChemistry, Multidisciplinary ; Nanoscience & Nanotechnology ; Materials Science, Multidisciplinary
WOS IDWOS:000911494900001
PublisherELSEVIER SCI LTD
Citation statistics
Document Type期刊论文
Identifierhttp://ir.ia.ac.cn/handle/173211/51055
Collection中国科学院分子影像重点实验室
Corresponding AuthorWang, Zihua; Wang, Kun; Tian, Jie; Zhao, Xinming
Affiliation1.Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Dept Diagnost Imaging, Beijing 100021, Peoples R China
2.Chinese Acad Sci, Inst Automat, Key Lab Mol Imaging, Beijing 100190, Peoples R China
3.Fujian Med Univ, Sch Basic Med Sci, Fujian Prov Key Lab Brain Aging & Neurodegenerat D, Fuzhou 350122, Fujian, Peoples R China
4.Hong Kong Univ Sci, Shenzhen Peking Univ, Shenzhen Hosp, Dept Hepatopancreato Biliary Surg, Guangzhou 518036, Peoples R China
5.Technol Med Ctr, Guangzhou 518036, Peoples R China
6.Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, State Key Lab Mol Oncol, Beijing 100021, Peoples R China
7.Natl Ctr Nanosci & Technol NCNST, CAS Ctr Excellence Nanosci, CAS Key Lab Biol Effects Nanomat Nanosafety, Beijing 100190, Peoples R China
First Author AffilicationInstitute of Automation, Chinese Academy of Sciences
Corresponding Author AffilicationInstitute of Automation, Chinese Academy of Sciences
Recommended Citation
GB/T 7714
Wang, Qian,Wang, Zihua,Li, Zhangfu,et al. Biomimetic camouflaged nanoparticle-based folfirinox platform for optimizing clinical pancreatic cancer treatment[J]. NANO TODAY,2023,48:11.
APA Wang, Qian.,Wang, Zihua.,Li, Zhangfu.,Li, Dan.,He, Fangfei.,...&Zhao, Xinming.(2023).Biomimetic camouflaged nanoparticle-based folfirinox platform for optimizing clinical pancreatic cancer treatment.NANO TODAY,48,11.
MLA Wang, Qian,et al."Biomimetic camouflaged nanoparticle-based folfirinox platform for optimizing clinical pancreatic cancer treatment".NANO TODAY 48(2023):11.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Wang, Qian]'s Articles
[Wang, Zihua]'s Articles
[Li, Zhangfu]'s Articles
Baidu academic
Similar articles in Baidu academic
[Wang, Qian]'s Articles
[Wang, Zihua]'s Articles
[Li, Zhangfu]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Wang, Qian]'s Articles
[Wang, Zihua]'s Articles
[Li, Zhangfu]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.